WELLS FARGO & COMPANY/MN - PROTEOSTASIS THERAPEUTICS IN ownership

Quarter-by-quarter ownership
WELLS FARGO & COMPANY/MN ownership history of PROTEOSTASIS THERAPEUTICS IN
ValueSharesWeighting
Q3 2020$69,000
-23.3%
62,982
-4.1%
0.00%
Q2 2020$90,00065,686
+28583.8%
0.00%
Q1 2020$0
-100.0%
229
-97.0%
0.00%
Q2 2019$8,000
-89.6%
7,706
-87.3%
0.00%
Q1 2019$77,000
-64.7%
60,890
-10.0%
0.00%
Q4 2018$218,000
+175.9%
67,633
+104.1%
0.00%
Q3 2018$79,000
-16.0%
33,138
-1.8%
0.00%
Q2 2018$94,000
+224.1%
33,745
+462.4%
0.00%
Q1 2018$29,000
-17.1%
6,0000.0%0.00%
Q4 2017$35,000
+52.2%
6,000
-43.7%
0.00%
Q3 2017$23,000
+64.3%
10,665
+255.5%
0.00%
Q2 2017$14,000
-70.2%
3,000
-49.8%
0.00%
Q1 2017$47,000
+74.1%
5,980
+174.3%
0.00%
Q4 2016$27,000
-20.6%
2,1800.0%0.00%
Q3 2016$34,0002,1800.00%
Other shareholders
PROTEOSTASIS THERAPEUTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 3,804,027$17,803,0002.95%
HARBOURVEST PARTNERS LLC 440,627$2,062,0000.89%
NEA Management Company, LLC 3,556,778$16,646,0000.61%
Rock Springs Capital Management LP 450,000$2,106,0000.11%
Bain Capital Public Equity Management, LLC 263,498$1,233,0000.07%
ELEMENT CAPITAL MANAGEMENT LLC 65,973$309,0000.06%
Hillhouse Capital Management 865,923$4,053,0000.06%
SABBY MANAGEMENT, LLC 125,151$586,0000.04%
Marshall Wace North America L.P. 684,124$3,421,0000.02%
FNY Partners Fund LP 20,127$94,0000.02%
View complete list of PROTEOSTASIS THERAPEUTICS IN shareholders